Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...
Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...
A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...
Photo Credit: AHA/Scott Morgan 2022. Used with permission. CHICAGO, IL—Full results of the RAPID trial testing etripamil nasal spray for patients with paroxysmal supraventricular tachycardia (PSVT) ...
A nasal spray containing the investigational calcium channel blocker etripamil is efficacious and safe in patients with paroxysmal supraventricular tachycardia, topline results suggest. The RAPID ...
HealthDay News — An experimental nasal spray, etripamil, may benefit patients with paroxysmal supraventricular tachycardia (PSVT), according to a study presented at the annual meeting of the Heart ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Supported by a grant (HE 12373) from the Public Health Service and a grant from the San Diego County Heart Association. We are indebted to Dr. David B. Carmichael, who referred the patient for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results